Clinical Trial Update: A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus Infection [Phase 2]

View source ↗

Summary

Phase 2 trial of JNJ-73763989 with pegylated interferon alpha-2a and nucleos(t)ide analogs in chronic hepatitis B was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• JNJ-73763989
• Nucleos(t)ide analogs
• Pegylated Interferon Alpha-2a (pegylated interferon alfa-2a)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Hepatitis B, Chronic | Phase 2 | Status: TERMINATED | Results posted: 2024-03-06